Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer
Explore this paper's citation graph
Summary
This review focuses on major mechanisms of epigenetic regulation mainly in lung cancer with recent data on EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit ), the catalytic subunit of the PRC2 (Polycomb Group PcG), that behaves as an oncogene in lungcancer associated with gene repression, non-coding RNAs and the epitranscriptome.
- Type
- review
- Published
- 2017-06-24
- Cited by
- 30
- References
- 113
- Access
- Open access
- OpenAlex
- https://openalex.org/W2651879272
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:10439071
Keywords
Epigenome, Epithelial–mesenchymal transition, Reprogramming, Metastasis, PRC2
References
- SnapShot: non-small cell lung cancer.
- A double take on bivalent promoters.
- ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
- Detecting RNA modifications in the epitranscriptome: predict and validate
- Epigenetics in lung cancer diagnosis and therapy
- ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells.
- Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
- Brief Report: The lincRNA Hotair Is Required for Epithelial‐to‐Mesenchymal Transition and Stemness Maintenance of Cancer Cell Lines
- Implications of the Hybrid Epithelial/Mesenchymal Phenotype in Metastasis
- Comprehensive genomic profiles of small cell lung cancer
- KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer.
- Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
- Long Noncoding RNAs in Lung Cancer.
- Epithelial-mesenchymal transitions in development and disease.
- Molecular mechanisms of epithelial–mesenchymal transition
- Induction of E-cadherin in Lung Cancer and Interaction with Growth Suppression by Histone Deacetylase Inhibition
- Epigenetic control of epithelial-mesenchymal-transition in human cancer.
- Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker
- The epigenetics of epithelial-mesenchymal plasticity in cancer
- Epigenetic biomarkers in lung cancer.
Cited by
- Prognostic values of distinct CBX family members in breast cancer
- Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes.
- Long term exposure to environmental concentrations of diesel exhaust particles does not impact the phenotype of human bronchial epithelial cells.
- Epigenetic Mechanisms Governing Behavioral Reprogramming in the Ant Camponotus floridanus
- EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
- Interferon Consensus Sequence-Binding Protein 8, a Tumor Suppressor, Suppresses Tumor Growth and Invasion of Non-Small Cell Lung Cancer by Interacting with the Wnt/β-Catenin Pathway
- Bioactive Natural Products From the Genus Kalanchoe as Cancer Chemopreventive Agents: A Review
- Nanotechnology in metastatic cancer treatment: Current Achievements and Future Research Trends
- The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial–mesenchymal transition in resected lung adenocarcinoma
- The Root Bark of Morus alba L. Suppressed the Migration of Human Non-Small-Cell Lung Cancer Cells through Inhibition of Epithelial–Mesenchymal Transition Mediated by STAT3 and Src
- Regulatory networks between Polycomb complexes and non-coding RNAs in the central nervous system
- Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review
- IRF8 induces senescence of lung cancer cells to exert its tumor suppressive function
- EZH2抑制剂与吉非替尼联合应用在EGFR-TKIs耐药肺癌细胞中的作用研究
- Retracted Article: Long noncoding RNA ANRIL knockdown increases sensitivity of non-small cell lung cancer to cisplatin by regulating the miR-656-3p/SOX4 axis
- LncRNA FOXC2 antisense transcript accelerates non-small-cell lung cancer tumorigenesis via silencing p15.
- p53-inducible SESTRINs might play opposite roles in the regulation of early and late stages of lung carcinogenesis
- Upregulated Long Non-Coding RNA LL22NC03-N64E9.1 Promotes the Proliferation and Migration of Human Breast Cancer Cells by Silencing Kruppel-Like Factor 2 Expression
- Novel evidence for m6A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer
- MicroRNA signature of small‐cell lung cancer after treatment failure: impact on oncogenic targets by miR‐30a‐3p control
Related papers
- Targeting EZH2 as cancer therapy.
- Targeting EZH2 for Cancer Therapy: Progress and Perspective
- Enhancer of zeste homolog 2: A potential target for tumor therapy.
- The noncanonical role of EZH2 in cancer
- Abstract 5436: HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities
- Non-canonical functions of the Polycomb group protein EZH2 in breast cancer.
- Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
- Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma
- Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors
- Inhibition of Polycomb Repressive Complex 2 activity reduces trimethylation of H3K27 and affects development in Arabidopsis seedlings